INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $261,000 | -44.1% | 3,926 | -33.1% | 0.47% | -31.7% |
| Q2 2019 | $467,000 | -27.5% | 5,872 | +2.0% | 0.69% | -20.8% |
| Q1 2019 | $644,000 | +80.9% | 5,756 | +62.9% | 0.87% | +11.4% |
| Q4 2018 | $356,000 | -29.5% | 3,534 | -11.6% | 0.78% | -35.0% |
| Q3 2018 | $505,000 | +50.7% | 3,998 | 0.0% | 1.21% | +65.9% |
| Q2 2018 | $335,000 | +20.9% | 3,998 | -11.1% | 0.73% | +33.9% |
| Q1 2018 | $277,000 | +25.3% | 4,496 | +19.0% | 0.54% | +184.3% |
| Q4 2017 | $221,000 | -15.0% | 3,779 | -15.7% | 0.19% | -18.0% |
| Q3 2017 | $260,000 | +18.2% | 4,481 | +146.2% | 0.23% | +15.3% |
| Q2 2017 | $220,000 | -41.3% | 1,820 | -45.0% | 0.20% | -27.3% |
| Q1 2017 | $375,000 | +61.6% | 3,312 | +55.1% | 0.28% | +50.3% |
| Q4 2016 | $232,000 | +7.9% | 2,135 | +63.5% | 0.18% | +52.9% |
| Q3 2016 | $215,000 | – | 1,306 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |